Transplants can be classified by the species involved:
- Autogeneic (autotransplant): donor and recipient are the same individual, so there are no rejection problems.
- Isogeneic (isotransplant): donor and recipient belong to the same species and are genetically and antigenically identical (identical twins or syngeneic animals). There are likewise no rejection problems.
- Allogeneic (allotransplant): donor and recipient belong to the same species but are antigenically different. There are rejection problems. This is the most common type.
- Xenogeneic (xenotransplant): donor and recipient are individuals of different species. There are serious rejection problems (protectin).

Practically everything can be transplanted.
- Cornea: the most frequently transplanted tissue. It is taken from cadavers. HLA compatibility is not necessary.
- Skin: taken from the patient themselves, so it is an autotransplant. A skin expander is used and the skin is then transplanted (living individuals). No compatibility or testing is necessary.
- Blood: it is transfused from a living donor and is normally given as blood products (fractions). Only ABO compatibility and Rh are sought, not HLA, because neither erythrocytes nor platelets have HLA (although purification is often not 100% effective and leucocytes are present).
- Lung and heart: always from cadavers. The time that passes between removal of the organ from the cadaveric donor and its transplantation into the recipient is not enough to carry out tests; there is no time. They would benefit from HLA testing, but it is not done because of the short life of organs once they have been removed. The most frequent procedure is combined transplantation of both organs but, if that is not the case, heart transplantation is more common.
- Pancreas: from cadaveric donors, and there is no time to assess compatibility. The pancreatic islets are isolated. HLA compatibility is assessed only in the case of a combined transplant with a kidney.
- Liver: always from a cadaver, but partial transplantation of lobes from a living donor has begun to be done. HLA compatibility is not usually assessed, although the transplant would benefit from it, because there is not much margin of time.
- Kidney: from a cadaver or a living donor. Compatibility tests are always carried out, because it is the organ that survives the most hours outside the donor, kept in preservation fluid, so maximum compatibility is sought.
- Bone marrow (haematopoietic precursors): 100% compatibility is necessary. Transplantation is done from living donors or from cord blood cells (cryopreserved samples).

CLASSIFICATION ACCORDING TO COMPATIBILITY:
- Not needed (skin, cornea and blood).
- Cannot be done because of the lability of the organ (heart, lungs, pancreas, liver).
- Can be done and is done (kidney, pancreas, bone marrow).
- Essential (bone marrow)
Incompatibilities
If appropriate compatibility testing and drugs are not used, transplant rejection occurs. Rejection has been classified by the time at which it appears:
- Hyperacute: the most immediate; it occurs within minutes or hours. It is mediated by preformed antibodies: anti-ABO or anti-HLA-I. A cross-match test is done to avoid this type of rejection. This rejection can appear on the operating table (for example, when the clamps are removed the antigen–antibody reaction takes place and the kidney begins to become necrotic) and the transplanted organ has to be removed because it becomes necrotic rapidly.
- Anti-HBO: antibodies are generated in blood transfusions, because a small fraction of leucocytes always remains after purification, and these cause rejection in the recipient's body (blood products with HLA in which there are contaminating leucocytes).
- Anti-HLA-I: they arise for two reasons: in women with more than one child, who have anti-HLA antibodies against the father's antigens, or in individuals who have received multiple transfusions.
- Accelerated acute: mediated by memory cells. It can also be prevented by means of cells.
- Acute: the least frequent. The transplant has gone on to work and to become vascularised. Rejection occurs from the 5th–7th day up to months later. There are two variants: cellular acute rejection, mediated by cells, and vascular acute rejection, mediated by antibodies. It is treated by immunosuppression.
- Chronic: the graft works well but at some point cellular rejection occurs. It is the slowest and it can be tackled therapeutically with immunosuppression (it is the easiest to control pharmacologically).
